Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL37A pseudogenes are sequences in the genome that show high similarity to the functional RPL37A gene, which encodes a ribosomal protein that is a component of the 60S ribosomal subunit[1][2]. These pseudogenes arise mainly through retrotransposition and are noncoding: that is, they do not produce a functional protein product[2]. While the parental RPL37A gene is involved in protein synthesis as part of the ribosome, RPL37A pseudogenes are generally considered "genomic fossils" and do not have protein-coding potential or serve as receptors, enzymes, or transporters[2][4]. However, some pseudogenes may participate in gene regulation at the RNA level through mechanisms such as serving as endogenous small RNAs, antisense RNAs, or competing endogenous RNAs, potentially modulating cellular processes indirectly[4][5]. There is no evidence that RPL37A pseudogenes are therapeutic targets, nor are there drugs known to act on them, nor are they established as biomarkers or linked to any particular adverse effects[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RPL37A pseudogene (RPL37AP4).